Researchers at the University of Toronto see a future where a single injection under the eyelid could replace months of daily ...

Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.